COMPANY PROFILE

Eureka Bio

Explore full profile

A biotechnology company that offers solutions for cancer immunotherapy

Shenzhen, ChinaFounded 2014Biotech & Life Sciences

Valuation $100–250M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Eureka Bio

EurekaBio is a pioneering company in the field of cell and gene therapy, specializing in the development and industrialization of cutting-edge technology platforms and products. The company serves clients in the biotechnology and pharmaceutical sectors, focusing on automating the processing of blood samples to concentrate cells, remove platelets, and separate PBMCs (Peripheral Blood Mononuclear Cells). EurekaBio operates in the highly specialized market of cell and gene therapy, where precision and innovation are paramount. The business model revolves around providing advanced automated equipment and viral vector research and development services. Revenue is generated through the sale of these specialized equipment and services, catering to the needs of domestic and international clients who require high-quality, reliable solutions for their therapeutic research and development projects.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Shenzhen, China
Employees: 13
Open positions: None listed
Dealroom signal: 53.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Feb 2024	$41M	$165M	Tasly Capital · Guangdong Technology Financial Group · ABC Capital · Dachen Caizhi	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Eureka Bio website traffic

Latest recorded traffic for Eureka Bio is 1.5K monthly website visits, up 36.4% over the last three months. Eureka Bio's team grew 30% over the past year.

Latest monthly visits1.5K 3-month web change+36.4% 1-year team growth+30%

Monthly website visitsFeb 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PLPLTTECHEngages in the R&D of single-cell precision research solutions	Hangzhou, China	Operational	—	$1.4M	—
ETENSEM TherapeuticsBiotechnology company focusing on high value and difficult-to-drug oncology targets	Medford, United States	Operational
WMWeiyan MedicalA provider of infection precision medicine products and services	Dongcheng District, China	Operational
REReplayReprogramming biology by writing and delivering big DNA	San Diego, United States	Acquired
NPNaegis PharmaceuticalsInnovative small molecule therapies targeting inflammatory mediators for serious eye diseases	Vancouver, Canada	Operational
ACActiTrexxA safe and efficient treatment option for transplanted patients providing substantial improvement of survival rate and quality of life	Mainz, Germany	Operational
RBRage BiotechRAGE Biotech is developing new approaches to modulate the receptor for advanced glycation end-products (RAGE), an important target in chronic inflammation	Melbourne, Australia	Operational
CTCytovia TherapeuticsDevelops transformational cancer immunotherapies and addresses several unmet medical needs for cancer prevention	Aventura, United States	Operational